retatrutide phase 2 nejm 2023 obesity trial results For patients with #obesity, semaglutide, a glucagon-like peptide-1 receptor agonist, is approved for weight management as a once-weekly subcutaneous injection. In a previous trial, oral semaglutide at a dose of 50 mg Retatrutide Phase 2 NEJM Trial:

A nationwide cohort study from Sweden and Denmark found no significant increase in suicide deaths among GLP-1 RA users compared to Sodium-glucose cotransporter-2 (SGLT2) inhibitors, and even reported a lower incidence of combined suicide and self-harm outcomes (HR 0.83) [47]

doi: 10.1016/j.cmet.2013.01.003 67 SchaapF

Phytomedicine 122, 155165

62% of US beauty and personal care buyers are interested in hyper-personalized products, and 28% are willing to pay extra for them

Steven Heymsfield of Pennington Biomedical Research Center describes the results of the BELIEVE study, which showed that the therapy combination addressed lean mass loss associated with GLP-1-based therapies